The prognostic importance of thrombocytopenia

Comprehensive, near real-time national systemic anti-cancer therapy (SACT) data: descriptive study of implementation and applications in Scotland (UK) from 2014.

ESMO real world data and digital oncology·2026

Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study.

ESMO open·2021

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2018

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

Breast cancer research and treatment·2017

LDL-C target achievement in people living with HIV: impact of combination lipid-lowering therapy. A retrospective cohort analysis.

AIDS (London, England)·2026

Longitudinal trends in copy-years viremia associated with mpox acquisition but not mpox severity in people with HIV.

AIDS (London, England)·2026

Sex differences in long-acting cabotegravir trough concentrations in the SEARCH study in Kenya and Uganda.

AIDS (London, England)·2026

Changes in neurodevelopmental outcomes from 24 to 36 months among children HIV-exposed uninfected (CHEU) and HIV-unexposed (CHU).

AIDS (London, England)·2026

Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.

AIDS (London, England)·2026

Ninety-six-week observational outcomes of long-acting injectable HIV therapy in people with adherence challenges, including people who use drugs.

AIDS (London, England)·2026

Evaluating deucrictibant for the treatment of hereditary angioedema.

Expert opinion on pharmacotherapy·2026

Managing What You Cannot Measure: Anesthetic Implications of Takayasu's Arteritis in Hypertensive Intracranial Hemorrhage.

Annals of African medicine·2026

A Decade‑Long Genetic Epidemiological Profile of Thalassemia in the Childbearing‑Age Population of Huizhou, a Major Hakka Center in Guangdong, China.

Hemoglobin·2026

Tripterygium Glycosides Alleviates Hemophagocytic Lymphohistiocytosis Accompanied With Aggressive NK Cell Leukemia and Epstein-Barr Virus Infection.

Journal of medical virology·2026

Post-procedural access blood flow and repeat endovascular intervention in hemodialysis vascular access: a recurrent-event cohort study.

Renal failure·2026

Beta Thalassemia Carrier Detection in Individuals with Borderline Normal Hemoglobin A2 Levels.

Hemoglobin·2026

Related Experiment Videos

The prognostic importance of thrombocytopenia

Related Concept Videos

Comprehensive, near real-time national systemic anti-cancer therapy (SACT) data: descriptive study of implementation and applications in Scotland (UK) from 2014.

Variation in chemotherapy prescribing rates and mortality in early breast cancer over two decades: a national data linkage study.

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial.

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial.

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

LDL-C target achievement in people living with HIV: impact of combination lipid-lowering therapy. A retrospective cohort analysis.

Longitudinal trends in copy-years viremia associated with mpox acquisition but not mpox severity in people with HIV.

Sex differences in long-acting cabotegravir trough concentrations in the SEARCH study in Kenya and Uganda.

Changes in neurodevelopmental outcomes from 24 to 36 months among children HIV-exposed uninfected (CHEU) and HIV-unexposed (CHU).

Reframing analytical treatment interruption through participants' and decliners' eyes: insights from an HIV remission trial.

Ninety-six-week observational outcomes of long-acting injectable HIV therapy in people with adherence challenges, including people who use drugs.

Evaluating deucrictibant for the treatment of hereditary angioedema.

Managing What You Cannot Measure: Anesthetic Implications of Takayasu's Arteritis in Hypertensive Intracranial Hemorrhage.

A Decade‑Long Genetic Epidemiological Profile of Thalassemia in the Childbearing‑Age Population of Huizhou, a Major Hakka Center in Guangdong, China.

Tripterygium Glycosides Alleviates Hemophagocytic Lymphohistiocytosis Accompanied With Aggressive NK Cell Leukemia and Epstein-Barr Virus Infection.

Post-procedural access blood flow and repeat endovascular intervention in hemodialysis vascular access: a recurrent-event cohort study.

Beta Thalassemia Carrier Detection in Individuals with Borderline Normal Hemoglobin A2 Levels.

Related Experiment Videos

The prognostic importance of thrombocytopenia

Related Concept Videos

Related Articles